Home LiteratureArticle Details
PMID: 21345945 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Journal of virology ·Vol. 85 ·No. 10 ·2011-05-00 ·Pages 4772-82

Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, Sankaran-Walters S, Syvanen M, Wong JK, George MD, Dandekar S

Abstract

Interruption of suppressive highly active antiretroviral therapy (HAART) in HIV-infected patients leads to increased HIV replication and viral rebound in peripheral blood. Effects of therapy interruption on gut-associated lymphoid tissue (GALT) have not been well investigated. We evaluated longitudinal changes in viral replication and emergence of viral variants in the context of T cell homeostasis and gene expression in GALT of three HIV-positive patients who initiated HAART during primary HIV infection but opted to interrupt therapy thereafter. Longitudinal viral sequence analysis revealed that a stable proviral reservoir was established in GALT during primary HIV infection that persisted through early HAART and post-therapy interruption. Proviral variants in GALT and peripheral blood mononuclear cells (PBMCs) displayed low levels of genomic diversity at all times. A rapid increase in viral loads with a modest decline of CD4(+) T cells in peripheral blood was observed, while gut mucosal CD4(+) T cell loss was severe following HAART interruption. This was accompanied by increased mucosal gene expression regulating interferon (IFN)-mediated antiviral responses and immune activation, a profile similar to those found in HAART-naive HIV-infected patients. Sequence analysis of rebound virus suggested that GALT was not the major contributor to the postinterruption plasma viremia nor were GALT HIV reservoirs rapidly replaced by HIV rebound variants. Our data suggest an early establishment and persistence of viral reservoirs in GALT with minimal diversity. Early detection of and therapy for HIV infection may be beneficial in controlling viral evolution and limiting establishment of diverse viral reservoirs in the mucosal compartment.

MeSH Terms
Adult Anti-HIV Agents/administration & dosage Antiretroviral Therapy, Highly Active Cluster Analysis HIV/classification,genetics,isolation & purification HIV Infections/drug therapy,virology Humans Intestinal Mucosa/virology Leukocytes, Mononuclear/virology Male Phylogeny Plasma/virology Polymorphism, Genetic Proviruses/classification,genetics,isolation & purification Viremia Withholding Treatment
Chemicals
Anti-HIV Agents
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Lerner Paula
Dept. of Medical Microbiology and Immunology, GBSF, Room 5511, University of California, Davis, California 95616, USA.
Guadalupe Moraima
Donovan Richard
Hung Jason
Flamm Jason
Prindiville Thomas
Sankaran-Walters Sumathi
Syvanen Michael
Wong Joseph K
George Michael D
Dandekar Satya
References (46)
46 references, click to expand
  1. A statistical test for detecting geographic subdivision.
    Mol Biol Evol. 1992 Jan;9(1):138-51 PMID: 1552836
  2. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.
    J Virol. 2008 Jan;82(1):538-45 PMID: 17959677
  3. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.
    J Virol. 2003 Mar;77(5):3229-37 PMID: 12584346
  4. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data.
    Bioinformatics. 2009 Jun 1;25(11):1451-2 PMID: 19346325
  5. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    N Engl J Med. 1999 May 27;340(21):1614-22 PMID: 10341273
  6. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93 PMID: 11687611
  7. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    J Infect Dis. 2005 Nov 15;192(10):1787-93 PMID: 16235178
  8. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Nature. 1997 May 8;387(6629):183-8 PMID: 9144289
  9. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration.
    J Virol. 2005 Mar;79(5):2709-19 PMID: 15708990
  10. Compartmentalization of the gut viral reservoir in HIV-1 infected patients.
    Retrovirology. 2007 Dec 04;4:87 PMID: 18053211
  11. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.
    Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9860-5 PMID: 15980151
  12. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
    Nat Med. 1999 May;5(5):512-7 PMID: 10229227
  13. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.
    J Virol. 2006 Aug;80(16):8236-47 PMID: 16873279
  14. Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV).
    AIDS Res Hum Retroviruses. 2008 Apr;24(4):561-71 PMID: 18426336
  15. Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.
    J Virol Methods. 2010 Sep;168(1-2):114-20 PMID: 20451557
  16. Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-1beta expression and display antiviral cytotoxic activity despite severe CD4(+) T-cell depletion in primary simian immunodeficiency virus infection.
    J Virol. 1998 Aug;72(8):6421-9 PMID: 9658083
  17. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.
    J Virol. 2005 Jul;79(14):9026-37 PMID: 15994796
  18. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
    Nat Protoc. 2009;4(1):44-57 PMID: 19131956
  19. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes.
    J Virol. 1998 Aug;72(8):6646-56 PMID: 9658111
  20. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells.
    J Virol. 2008 Apr;82(8):4016-27 PMID: 18272585
  21. Pathogenesis of HIV in the gastrointestinal tract.
    Curr HIV/AIDS Rep. 2007 Feb;4(1):10-5 PMID: 17338855
  22. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.
    J Virol. 2010 Mar;84(5):2395-407 PMID: 20015984
  23. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals.
    Virol J. 2005 Feb 14;2:11 PMID: 15710048
  24. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses.
    Mucosal Immunol. 2008 Nov;1(6):475-88 PMID: 19079215
  25. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.
    J Virol. 1999 Nov;73(11):9404-12 PMID: 10516049
  26. DAVID: Database for Annotation, Visualization, and Integrated Discovery.
    Genome Biol. 2003;4(5):P3 PMID: 12734009
  27. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
    AIDS. 2001 Jun 15;15(9):F19-27 PMID: 11416734
  28. HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy.
    J Leukoc Biol. 2004 Sep;76(3):562-70 PMID: 15218056
  29. HIV RNA in plasma rebounds within days during structured treatment interruptions.
    AIDS. 2003 Jan 24;17(2):195-9 PMID: 12545079
  30. A robust measure of HIV-1 population turnover within chronically infected individuals.
    Mol Biol Evol. 2004 Oct;21(10):1902-12 PMID: 15215321
  31. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Science. 1997 Nov 14;278(5341):1295-300 PMID: 9360927
  32. HIV pathogenesis: 25 years of progress and persistent challenges.
    AIDS. 2009 Jan 14;23(2):147-60 PMID: 19098484
  33. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.
    Nat Med. 2000 Jul;6(7):757-61 PMID: 10888923
  34. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
    J Infect Dis. 2010 Nov 15;202(10):1553-61 PMID: 20939732
  35. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.
    J Virol. 2003 Nov;77(21):11708-17 PMID: 14557656
  36. Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations.
    PLoS One. 2009 Sep 22;4(9):e7122 PMID: 19771165
  37. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.
    J Clin Invest. 2000 Oct;106(7):839-45 PMID: 11018071
  38. HIV rebounds from latently infected cells, rather than from continuing low-level replication.
    Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16725-30 PMID: 18936487
  39. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.
    AIDS. 2002 Nov 22;16(17):2342-4 PMID: 12441810
  40. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
    J Infect Dis. 2001 Jan 1;183(1):36-50 PMID: 11106537
  41. The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials.
    Curr Opin HIV AIDS. 2006 Jan;1(1):62-8 PMID: 19372786
  42. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7 PMID: 18490657
  43. Immunologic and virologic events in early HIV infection predict subsequent rate of progression.
    J Infect Dis. 2010 Jan 15;201(2):272-84 PMID: 20001854
  44. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.
    J Exp Med. 2001 Jan 15;193(2):169-80 PMID: 11148221
  45. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52 PMID: 12370434
  46. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.
    Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7 PMID: 10737796
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2011-05-00
Epub
2011-00-23
Pages
4772-82
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC3126205
Subset
IM
Grants
NICHD NIH HHS · K12 HD051958 · United States
NIAID NIH HHS · R01 AI043274 · United States
NIDDK NIH HHS · DK61297 · United States
NIDDK NIH HHS · R01 DK061297 · United States
NIAID NIH HHS · AI43274 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]